In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer.

Key topics included:

The definition and characteristics of high-risk non-muscle invasive bladder cancer.
Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment.
The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach.
Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy.

Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes.

Follow us on social media:

⁠X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

#NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks